Has Alice Reier, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,355 in general payments to Alice Reier, MD across 322 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alice Reier, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alice Reier, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alice Reier, MD

Hematology & Oncology · Oakland, CANPI 1922074731

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,131 of the $7,355 with a category attached, or 83.4%. It is spread thinly across 40 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,216 and has fallen 90.9% since, to $202 in 2023.

$7,355in general payments, 2019–2025

Across 322 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$1K
Johnson & Johnson$932
Takeda Pharmaceuticals U.S.A., Inc.$752
Seagen Inc.$539
Amgen$498
E.r. Squibb & Sons, L.L.C.$410
plus $3K from 34 others

What the payments were for

Food & beverage$6,13183%
Education$5758%
Other$6499%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	26	$1,001
Johnson & Johnson(2 entities)	39	$932
Takeda Pharmaceuticals U.S.A., Inc.	50	$752
Seagen Inc.	25	$539
Amgen	16	$498
E.r. Squibb & Sons, L.L.C.	18	$410
AstraZeneca(2 entities)	18	$394
Pfizer	14	$261
Bristol Myers Squibb	10	$239
GSK	10	$234
Incyte Corporation	9	$226
Merck	10	$183
Pharmacyclics LLC, An Abbvie Company	8	$162
Daiichi Sankyo Inc.	8	$160
Sanofi	7	$156
Gilead(2 entities)	7	$145
Dova Pharmaceuticals	6	$128
Sanofi-aventis U.S. LLC	1	$100
Lilly USA, LLC	5	$82
Boehringer Ingelheim	4	$77
Genentech USA, Inc.	4	$76
Exelixis Inc.	3	$72
Regeneron Healthcare Solutions, Inc.	2	$50
Tesaro, Inc.	2	$50
Eisai Inc.	2	$43
Bayer	2	$42
Epizyme, Inc.	2	$40
Acceleron Pharma, Inc.	1	$34
AMAG Pharmaceuticals, Inc.	2	$33
Myovant Sciences Inc.	1	$27
Dendreon Pharmaceuticals LLC	1	$26
Taiho Oncology, Inc.	1	$25
ADC Therapeutics America, Inc.	1	$25
AbbVie	1	$24
Teva Pharmaceuticals USA, Inc.	1	$22
AVEO Pharmaceuticals, Inc.	1	$19
Lexicon Pharmaceuticals, Inc.	1	$19
Clovis Oncology, Inc.	1	$17
CTI Biopharma Corp.	1	$17
Coherus Oncology, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Pomalyst$124

How this compares

$7,355 in reported general payments places this provider in the 60th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Medicare billing

Part B allowed, 2024

$9,782

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Oakland

Dennis SlamonLos Angeles$3.1M
Sandra HorningStanford$2.5M
Mohammadbagher ZiariCorona$2.5M
George YaghmourLos Angeles$1.9M
Robert VescioWest Hollywood$1.1M
Kevin KellyLos Angeles$894K
Johnny ChangEncino$884K
Nitin RohatgiSacramento$814K
Omid HamidSanta Monica$809K
Catherine CoombsOrange$786K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →